| |
 |
Beijing ACCB Biotech Ltd, an innovative company
originated from Tsinghua University, was founded in June, 2004.
ACCB Biotech is dedicated to develop novel molecular cancer
detection and diagnostic technologies, and to commercialize
kits and services for cancer screening, early-stage cancer detection,
prognosis evaluation, personalized cancer therapies, and therapeutic
efficacy and reoccurrence monitoring.
|
|
ACCB Biotech believes that innovation is the foundation
of a company and that new technologies and products must meet
needs of the market and benefit the society. We have developed
patent-protected and SFDA-approved technology platforms (EnzymAct
and BiomarkXP),
and a rich pipeline. ACCB Biotech promises to provide our clients
with innovative and high-quality products and services, and
to become the leader of molecular cancer detection/diagnostics
in the new personalized therapy era.
|
|
|
ACCB Biotech has an innovative culture that fosters
an open working climate. In bringing together R&D capabilities
with marketing, business development, and sales teams as well
as our customers, ACCB Biotech creates a working environment
that encourages openness and the rapid exchange of new ideas
while at the same time ensures high-performance discipline in
development. |
|
|
 |
